Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet degranulation is a critical biological process in hemostasis, where activated platelets release the contents of their intracellular storage granules. This release amplifies platelet activation, recruits additional platelets, and modulates local cell signaling. The pathway involves various receptors (GPVI, GPIIb/IIIa), signaling molecules (TXA2), and SNARE proteins that mediate granule fusion with the plasma membrane or open canalicular system.
Drugs can inhibit platelet activation, granule release, or aggregation through various mechanisms, targeting receptors (e.g., P2Y12, GPIIb/IIIa) or intracellular signaling pathways.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet Degranulation Pathway (N/A).